Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
ASND 
Ascendis Pharma AS (ASND)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: ASND (1-star) is a SELL. SELL since 3 days. Simulated Profits (-5.14%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $260.92
1 Year Target Price $260.92
| 12 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.3% | Avg. Invested days 38 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.47B USD | Price to earnings Ratio - | 1Y Target Price 260.92 |
Price to earnings Ratio - | 1Y Target Price 260.92 | ||
Volume (30-day avg) 16 | Beta 0.44 | 52 Weeks Range 118.03 - 229.94 | Updated Date 12/14/2025 |
52 Weeks Range 118.03 - 229.94 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.47 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -36.03% | Operating Margin (TTM) 5.15% |
Management Effectiveness
Return on Assets (TTM) -7.69% | Return on Equity (TTM) -818.43% |
Valuation
Trailing PE - | Forward PE 51.55 | Enterprise Value 13789553625 | Price to Sales(TTM) 20.83 |
Enterprise Value 13789553625 | Price to Sales(TTM) 20.83 | ||
Enterprise Value to Revenue 18.17 | Enterprise Value to EBITDA -20.75 | Shares Outstanding 61098156 | Shares Floating 60628311 |
Shares Outstanding 61098156 | Shares Floating 60628311 | ||
Percent Insiders 0.76 | Percent Institutions 106.17 |
About Ascendis Pharma AS
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-01-28 | President, CEO, Member of Executive Board & Executive Director Mr. Jan Moller Mikkelsen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1017 | Website https://ascendispharma.com |
Full time employees 1017 | Website https://ascendispharma.com | ||
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.